Passage Bio, Inc.
PASGPassage Bio is a clinical-stage genetic medicines company focused on developing one-time AAV-based gene therapies for neurodegenerative diseases.
Table of contents
Earnings
Next report
Aug 11, 2026 (In 1 week)Competitors
By market cap
By revenue growth
Profile
Passage Bio is a clinical-stage genetic medicines company focused on developing one-time AAV-based gene therapies for neurodegenerative diseases. The company leverages a differentiated approach to CNS disorders by utilizing intra cisterna magna (ICM) administration to achieve widespread vector delivery to the brain and spinal cord. Its core value proposition lies in targeting underlying pathologies of conditions with high unmet needs, such as frontotemporal dementia and Huntington’s disease.
Passage Bio is a clinical-stage developer with a lead candidate in Phase 1/2 trials, utilizing a specialized ICM delivery method to differentiate itself from systemic gene therapy approaches.
Questions, answered.
- What is Passage Bio, Inc.'s market cap?
- Passage Bio, Inc. (PASG) has a market capitalization of $14.8M and trades on NASDAQ.
- Who are Passage Bio, Inc.'s competitors?
- Passage Bio, Inc.'s key competitors include Voyager Therapeutics, Inc., uniQure N.V., Denali Therapeutics Inc., and others. These companies compete in similar markets and product categories.
- Who does Passage Bio, Inc. partner with?
- Passage Bio, Inc.'s notable partners include Gemma Biotherapeutics, Inc., University of Pennsylvania, Catalent.
- Where is Passage Bio, Inc. headquartered?
- Passage Bio, Inc. is headquartered in United States of America and employs approximately 85 people. It has been publicly traded since 2020.